Regional Expression of Androgen Receptor Coregulators and Androgen Action in the Mouse Epididymis

2011 ◽  
Vol 32 (6) ◽  
pp. 711-717 ◽  
Author(s):  
P. Sipila ◽  
A. Krutskikh ◽  
D. A. Pujianto ◽  
M. Poutanen ◽  
I. Huhtaniemi
2002 ◽  
Vol 20 (6) ◽  
pp. 326-330 ◽  
Author(s):  
Takashi Sato ◽  
Hirotaka Kawano ◽  
Shigeaki Kato

2009 ◽  
Vol 94 (1) ◽  
pp. 277-284 ◽  
Author(s):  
Ilpo T. Huhtaniemi ◽  
Stephen R. Pye ◽  
Kate L. Limer ◽  
Wendy Thomson ◽  
Terence W. O'Neill ◽  
...  

2014 ◽  
Vol 21 (4) ◽  
pp. T105-T118 ◽  
Author(s):  
Christine Helsen ◽  
Thomas Van den Broeck ◽  
Arnout Voet ◽  
Stefan Prekovic ◽  
Hendrik Van Poppel ◽  
...  

Androgen deprivation is the mainstay therapy for metastatic prostate cancer (PCa). Another way of suppressing androgen receptor (AR) signaling is via AR antagonists or antiandrogens. Despite being frequently prescribed in clinical practice, there is conflicting evidence concerning the role of AR antagonists in the management of PCa. In the castration-resistant settings of PCa, docetaxel has been the only treatment option for decades. With recent evidence that castration-resistant PCa is far from AR-independent, there has been an increasing interest in developing new AR antagonists. This review gives a concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach.


2010 ◽  
Vol 24 (12) ◽  
pp. 2392-2405 ◽  
Author(s):  
Shuanggang Hu ◽  
Guangxin Yao ◽  
Xiaojun Guan ◽  
Zimei Ni ◽  
Wubin Ma ◽  
...  

The Prostate ◽  
2004 ◽  
Vol 62 (2) ◽  
pp. 133-139 ◽  
Author(s):  
Dacheng Ding ◽  
Lihua Xu ◽  
Mani Menon ◽  
G. Prem Veer Reddy ◽  
Evelyn R. Barrack

2015 ◽  
Vol 11 (12) ◽  
pp. 3347-3354 ◽  
Author(s):  
Hongli Liu ◽  
Xiaoli An ◽  
Shuyan Li ◽  
Yuwei Wang ◽  
Jiazhong Li ◽  
...  

R-Bicalutamide is a first generation antiandrogen used to treat prostate cancer, which inhibits androgen action by competitively binding to the androgen receptor (AR).


Endocrinology ◽  
2005 ◽  
Vol 146 (9) ◽  
pp. 4117-4126 ◽  
Author(s):  
Karel De Gendt ◽  
Nina Atanassova ◽  
Karen A. L. Tan ◽  
Luiz Renato de França ◽  
Gleydes Gambogi Parreira ◽  
...  

Abstract It is established that androgens and unidentified Sertoli cell (SC)-derived factors can influence the development of adult Leydig cells (LC) in rodents, but the mechanisms are unclear. We evaluated adult LC development and function in SC-selective androgen receptor (AR) knockout (SCARKO) and complete AR knockout (ARKO) mice. In controls, LC number increased 26-fold and LC size increased by approximately 2-fold between 12 and 140 d of age. LC number in SCARKOs was normal on d 12, but was reduced by more than 40% at later ages, although LC were larger and contained more lipid droplets and mitochondria than control LC by adulthood. ARKO LC number was reduced by up to 83% at all ages compared with controls, and LC size did not increase beyond d 12. Serum LH and testosterone levels and seminal vesicle weights were comparable in adult SCARKOs and controls, whereas LH levels were elevated 8-fold in ARKOs, although testosterone levels appeared normal. Immunohistochemistry and quantitative PCR for LC-specific markers indicated steroidogenic function per LC was probably increased in SCARKOs and reduced in ARKOs. In SCARKOs, insulin-like factor-3 and estrogen sulfotransferase (EST) mRNA expression were unchanged and increased 3-fold, respectively, compared with controls, whereas the expression of both was reduced more than 90% in ARKOs. Changes in EST expression, coupled with reduced platelet-derived growth factor-A expression, are potential causes of altered LC number and function in SCARKOs. These results show that loss of androgen action on SC has major consequences for LC development, and this could be mediated indirectly via platelet-derived growth factor-A and/or estrogens/EST.


Sign in / Sign up

Export Citation Format

Share Document